The purpose of this study is to identify and characterize patients with known Type 2 Diabetes Mellitus (T2DM) for possible participation in ongoing or future T2DM clinical studies, and to characterize trends in key concomitant medication use in this patient population across different geographical regions.
Participants must be ≥ 18 years of age at the time of signing the ICF.
Patients with a diagnosis of T2DM, test- or documentation-confirmed as per World
Lifestyle management alone, AND/OR
A stable dose of background glucose-lowering medication(s) for T2DM (As specified in the Protocol) for at least 45 days prior to signing the ICF.
Current or planned use of GLP-1 RAs prohibited in ongoing or future T2DM studies evaluating the efficacy and safety of investigational GLP-1 RAs (As specified in the Protocol).
Diagnosed with Type 1 diabetes mellitus.
Known pregnancy at the time of visit or having the intention to become pregnant.
Adults with Type 2 Diabetes
Cohort
Cross-sectional
Procedure: assessment
Other interventionThe approximate volume of blood required is 2 mL
Patient demographics
Summary statistics
Medical and surgical history
Summary statistics
Concomitant medication
Summary statistics
HbA1c levels
Summary statistics
Referral to ongoing or future T2DM study.
Number of participants with high likelihood of meeting eligibility criteria in ongoing or future T2DM studies, for referral to those studies.
Click on the lead sponsor to view all of their trials.